...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Transplant immunology >Sensitization to enhanced green fluorescence protein minor histocompatibility antigen by gene transduction into dendritic cells and peritoneal exudate macrophages.
【24h】

Sensitization to enhanced green fluorescence protein minor histocompatibility antigen by gene transduction into dendritic cells and peritoneal exudate macrophages.

机译：通过基因转导进入树突状细胞和腹膜分泌液巨噬细胞，增强绿色荧光蛋白次要组织相容性抗原的致敏作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Enhanced green fluorescence protein (EGFP) has been widely applied to gene transduction in cellular and molecular biology as a reporter element. When applied to cell transplantation, it raises fundamental issues concerning cell-associated antigens, in particular, a model of minor histocompatibility antigen(s). Although it is well known that immunological behavior of minor histocompatibility antigens mimic tumor associated antigens (TAA), identified genes coding minor histocompatibility antigens are few and far between. Inasmuch as immunity and tolerance to TAA are provided by immunological behavior of minor histocompatibility antigen such as histocompatibility antigen of the Y chromosome, H-Y, it occurs to us that transgenic as well as transduced EGFP provides a useful model system to be applied to tumor immunology. In this respect, genetic modification of specialized antigen-presenting cells (APC), i.e., dendritic cells (DC), such as gene transduction of EGFP into DC, would provide one of the most important strategies in transplantation as well as tumor immunology inasmuch as DC play a key role in initiating primary immune responses, As far as gene transduction into DC is concerned, others have reported that successful gene transduction occurs in DC by adenoviral vector systems. However, our previous studies concerning EGFP transduction into DC suggested that this view should be carefully examined and interpreted. Employing adenoviral and lentiviral vector systems as well as specialized APC of rat DC and peritoneal exudate macrophages (PEM), EGFP-transduced APC were examined to determine whether and to what extent the EGFP-transduced APC were able to sensitize non-transgenic littermates against transgenic EGFP as antigen(s). Thus EGFP-transgenic cardiac isografts were transplanted to non-transgenic littermates and examined to determine if sensitization of non-transgenic littermate recipients with the EGFP-transduced APC was able to reject the test grafts in an accelerated manner. In this study, we examined this and provide further evidence that widely used viral vector systems are unable to transfer the reporter gene EGFP into mature rat DC generated from bone marrow cells (BMC), driven by Flt3/Flk2 ligand and IL-6. Nevertheless, successful gene transduction was obtained by either applying a lentiviral vector system to the developing DC progenitor cells during a long-term culture of rat BMC or by applying an adenoviral vector system to PEM. Thus, successful gene transduction into specialized APC was verified by in vivo priming of non-transgenic littermates with the EGFP-transduced APC, followed by accelerated rejection of EGFP-transgenic cardiac isografts.
机译：增强型绿色荧光蛋白（EGFP）作为报告元件已广泛应用于细胞和分子生物学中的基因转导。当应用于细胞移植时，它引起了有关细胞相关抗原的基本问题，特别是次要组织相容性抗原的模型。尽管众所周知，次要组织相容性抗原的免疫学行为模仿了肿瘤相关抗原（TAA），但是鉴定出的编码次要组织相容性抗原的基因很少且相差甚远。由于较小的组织相容性抗原（例如Y染色体H-Y的组织相容性抗原）的免疫学行为提供了对TAA的免疫力和耐受性，因此我们发现转基因以及转导的EGFP提供了可用于肿瘤免疫学的有用模型系统。在这方面，对专门的抗原呈递细胞（APC），即树突状细胞（DC）进行基因修饰，例如将EGFP基因转导入DC，将为移植和肿瘤免疫学提供最重要的策略之一，因为DC在启动原发性免疫反应中起关键作用。就向DC的基因转导而言，其他人已报道腺病毒载体系统在DC中成功进行了基因转导。但是，我们先前有关EGFP转化为DC的研究表明，应仔细检查和解释这种观点。利用腺病毒和慢病毒载体系统以及大鼠DC和腹膜渗出巨噬细胞（PEM）的专门APC，检查了EGFP诱导的APC，以确定EGFP诱导的APC是否能够以及在何种程度上使非转基因同窝动物对转基因敏感EGFP作为抗原。因此，将EGFP转基因心脏同种异体移植到非转基因同窝动物中，并检查以确定用EGFP转导的APC对非转基因同窝动物受体的敏化是否能够以加速的方式拒绝测试移植物。在这项研究中，我们对此进行了检查，并提供了进一步的证据，表明广泛使用的病毒载体系统无法将报道基因EGFP转移到由Flt3 / Flk2配体和IL-6驱动的骨髓细胞（BMC）生成的成熟大鼠DC中。然而，通过在大鼠BMC的长期培养过程中将慢病毒载体系统应用于发育中的DC祖细胞，或通过将腺病毒载体系统应用于PEM，可以获得成功的基因转导。因此，通过用EGFP转导的APC在体内引发非转基因同窝动物，然后加速对EGFP转基因的心脏同种异体移植的排斥，证实了成功的基因转导至专门的APC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号